Sung Ji Nam
Stock Analyst at Scotiabank
(2.74)
# 1,778
Out of 5,173 analysts
83
Total ratings
47.83%
Success rate
4.85%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $84.96 | -29.38% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $52.00 | +44.23% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $190.00 | +44.74% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $478.12 | +23.40% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $123.79 | +0.98% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $25.75 | +55.34% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $14.69 | +172.29% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $4.66 | +28.76% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.46 | +173.97% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.39 | +43.88% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $104.91 | -30.42% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $13.66 | -12.15% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $301.81 | +49.10% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $44.50 | +39.33% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $33.54 | +31.19% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.56 | +99.32% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.92 | +105.48% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.33 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $84.96
Upside: -29.38%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $52.00
Upside: +44.23%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $190.00
Upside: +44.74%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $478.12
Upside: +23.40%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $123.79
Upside: +0.98%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $25.75
Upside: +55.34%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $14.69
Upside: +172.29%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $4.66
Upside: +28.76%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.46
Upside: +173.97%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.39
Upside: +43.88%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $104.91
Upside: -30.42%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $13.66
Upside: -12.15%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $301.81
Upside: +49.10%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $44.50
Upside: +39.33%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $33.54
Upside: +31.19%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.56
Upside: +99.32%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $2.92
Upside: +105.48%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.33
Upside: -